Tacrolimus - VIVUS

Drug Profile

Tacrolimus - VIVUS

Alternative Names: SPI-026; VI-0106

Latest Information Update: 16 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Selten Pharma; Stanford University
  • Developer VIVUS
  • Class Lactones; Macrolides; Skin disorder therapies
  • Mechanism of Action Bone morphogenetic protein receptor type II modulators; Calcineurin inhibitors; Cytokine inhibitors; T cell activation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pulmonary arterial hypertension
  • New Molecular Entity No

Highest Development Phases

  • Phase II Pulmonary arterial hypertension

Most Recent Events

  • 08 May 2018 VIVUS announces intention to submit IND to US FDA for Pulmonary arterial hypertension in the first half of 2018
  • 22 Sep 2017 Tacrolimus is still in clinical development for Pulmonary arterial hypertension in USA (Vivus annual report, Form 10-k,
  • 06 Sep 2017 Tacrolimus - Selten Pharma receives Orphan Drug status for Pulmonary arterial hypertension in European Union
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top